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stratification and new molecular targets will improve out-
comes. It is now clear that medulloblastoma is not a single-
disease entity, but instead consists of at least four distinct 
molecular subgroups: WNt/Wingless, Sonic Hedgehog, 
group 3, and group 4. the Medulloblastoma Down Under 
2013 meeting, which convened at Bunker Bay, Australia, 
brought together 50 leading clinicians and scientists. the 
2-day agenda included focused sessions on pathology and 
molecular stratification, genomics and mouse models, high-
throughput drug screening, and clinical trial design. the 
meeting established a global action plan to translate novel 
biologic insights and drug targeting into treatment regimens 
to improve outcomes. A consensus was reached in several 
key areas, with the most important being that a novel clas-
sification scheme for medulloblastoma based on the four 
molecular subgroups, as well as histopathologic features, 
Abstract Medulloblastoma is curable in approximately 
70 % of patients. Over the past decade, progress in improv-
ing survival using conventional therapies has stalled, result-
ing in reduced quality of life due to treatment-related side 
effects, which are a major concern in survivors. the vast 
amount of genomic and molecular data generated over the 
last 5–10 years encourages optimism that improved risk 
the third annual meeting of the International Medulloblastoma 
Working group took place at Bunker Bay, Western Australia, 
February 12–13, 2013. Fifty leading researchers and clinicians 
from Australia, Canada, France, germany, New Zealand, the 
United Kingdom, and the United States of America came 
together to discuss their most recent findings and create an 
international plan of action for medulloblastoma research. the 
group’s focus was on integrating novel biological insights gained 
from preclinical models and high-throughput drug screening 
(HtS) into the next generation of clinical trials.
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should be presented for consideration in the upcoming fifth 
edition of the World Health Organization’s classification of 
tumours of the central nervous system. three other notable 
areas of agreement were as follows: (1) to establish a cen-
tral repository of annotated mouse models that are readily 
accessible and freely available to the international research 
community; (2) to institute common eligibility criteria 
between the Children’s Oncology group and the Interna-
tional Society of paediatric Oncology europe and initi-
ate joint or parallel clinical trials; (3) to share preliminary 
high-throughput screening data across discovery labs to 
hasten the development of novel therapeutics. Medulloblas-
toma Down Under 2013 was an effective forum for mean-
ingful discussion, which resulted in enhancing international 
collaborative clinical and translational research of this rare 
disease. this template could be applied to other fields to 
devise global action plans addressing all aspects of a dis-
ease, from improved disease classification, treatment strati-
fication, and drug targeting to superior treatment regimens 
to be assessed in cooperative international clinical trials.
Introduction
Medulloblastoma is the most common malignant brain 
tumor of childhood. the disease affects one in five children 
who have a brain tumor [46]. the current World Health 
Organization’s (WHO) classification recognizes the classic 
medulloblastoma and four histological variants of medullo-
blastoma: anaplastic, large cell, nodular desmoplastic, and 
medulloblastoma with extensive nodularity (MBeN) [17]. 
Since the 1990s, risk stratification of medulloblastoma 
has been based on age, metastatic status at diagnosis, and 
extent of surgical resection. More recently, the presence of 
widespread anaplasia or large cell morphology was added 
to risk-stratification criteria after these cytologic pheno-
types were associated with decreased progression-free sur-
vival [2, 20, 21]. In contrast, nodular desmoplastic tumors 
are a favorable prognostic marker in infants [42]. Children 
older than 3 years with localized disease at diagnosis and 
who have undergone complete or near-complete tumor 
resection (<1.5 cm2 residual tumor) are classified as having 
average-risk disease. patients in this age group with meta-
static disease at diagnosis, incomplete tumor resection, dif-
fuse anaplasia, or large cell histology are classified as hav-
ing high-risk disease. Children younger than 3 years and 
infants comprise a separate clinical group.
Approximately 80 % of children treated in the average-
risk group are now long-term survivors. this group has a 
5- to 10-year disease control rate of 75 to 85 % after treat-
ment with the most commonly used approach, i.e., 23.4 gy 
craniospinal irradiation (CSI) and a posterior fossa boost to 
55.8 gy in combination with vincristine during CSI. Radio-
therapy is followed by maintenance chemotherapy using 
vincristine, cisplatin, and lomustine and/or cyclophospha-
mide [15, 32]. Survival for the high-risk group has also 
improved to 60–70 % [8, 11], achieved by using a higher 
dose of CSI (36–39.6 gy) and intensifying chemotherapy. 
However, these survival figures have plateaued, with little 
improvement seen in the past decade [14, 31, 33, 50, 51]. 
particularly troubling are the devastating long-term seque-
lae, including developmental, neurological, neuroendo-
crine, and psychosocial deficits and second tumors currently 
endured by survivors [16, 18, 19, 24, 25, 35, 36, 40, 47, 48].
the current explosion of molecular data has begun to 
elucidate the biologic makeup of medulloblastoma [26, 
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27, 34]. this information is expected to lead to improved 
disease classification, treatment stratification, and the dis-
covery of novel drug targets. Seminal array-based tran-
scriptional-profiling studies of large cohorts of primary 
medulloblastoma samples [1, 13, 28, 52] have divided 
medulloblastoma into at least four distinct subgroups: 
Wnt/Wingless (WNt), Sonic Hedgehog (SHH), group 3, 
and group 4 medulloblastoma [49]. these subgroups have 
distinct cytogenetic features, genetic aberrations, gene 
expression profiles, and divergent phenotypes including 
patient demographics, tumor cell histology, and outcomes 
[3–7, 38, 44]. More recently, single-nucleotide polymor-
phism (SNp) arrays and whole-genome and whole-exome 
sequencing have uncovered further the genetic landscape 
of medulloblastoma [12, 29, 37, 39, 41]. thus, what was 
once regarded a single-disease entity is now recognized as 
being at least four distinct diseases that require individual 
diagnostic and therapeutic approaches. to further improve 
cure rates and neurodevelopmental outcomes, future pro-
spective clinical trials will need to adopt an integrative 
classification system based on clinical, histopathologic, and 
molecular criteria. Determining these molecular subgroups 
at diagnosis is expected to significantly enhance risk clas-
sification and identify those patients most likely to bene-
fit from molecularly targeted therapies, as well as therapy 
reduction. the rapid accumulation of molecular data poses 
the clinical challenge of applying this data in a timely 
manner in clinical trials. An important element of the next 
generation of medulloblastoma clinical trials will be the 
robust assignment of subgroup status to inform clinical and 
research advances.
presented here is an account of the meeting, which was 
divided into four sessions: pathology and molecular stratifi-
cation, genomics and mouse models, high-throughput drug 
screening—translating science into the clinic, and clini-
cal trials—implementing advances into the next-genera-
tion protocols. the development and summary of a global 
action plan is given at the end of the report.
Meeting report
Session 1: pathology and molecular stratification
David ellison discussed the potential use of a combined 
molecular and histopathologic classification. Medulloblas-
toma is poised to be the first brain tumor to be defined pri-
marily by molecular subgroup and histopathologic features. 
the new scheme must maintain clinical utility, provide a 
clear link with the current histopathologic classification, be 
based upon robust, reproducible and specific assays, and be 
applicable in pathology laboratories around the world. Diag-
nostic pathologic evaluation would be based on a combina-
tion of standard histology, immunohistochemistry (IHC), 
and the application of molecular testing. Concerns about the 
subjectivity of histologic interpretations and the morphologic 
heterogeneity of medulloblastoma were raised, highlighting 
the need for a standardized method of histologic analysis.
On the basis of previously reported clinicopathologic 
correlates, Dr. ellison [4–6] suggested the following histo-
pathology-based classification for consideration (table 1).
torsten pietsch discussed the german experience with 
the brain tumor reference center for neuro-oncological 
studies and tissue bank center (Brain-Net, brain tissue bank 
Bonn). the center’s tasks include performing centralized 
reviews, providing second opinions on difficult cases, and 
developing new diagnostic tools and training. to minimize 
discordance between centers, digital “virtual” microscopy 
is often used to assist smaller centers, and reference pathol-
ogists meet regularly in an effort to reach a consensus about 
Table 1  Suggested medulloblastoma classification based on histo-
pathologic and molecular classification
LC/A large cell/anaplastic, MBEN medulloblastoma with extensive 
nodularity, SHH Sonic Hedgehog, WNT Wnt/Wingless
Molecular variant Morphologic classification
WNt subgroup Classic, LC/A
SHH subgroup Desmoplastic (nodular), including 
MBeN, classic, and LC/A
Non-WNt/non-SHH subgroup Classic, LC/A, differentiating, 
melanotic, medullomyoblastoma
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the percentage of features that constitute a certain disease 
classification. the process of tissue banking was discussed, 
and the requirements of a successful bank included a 
decentralized tumor repository, written and informed con-
sent, intense coordination and cooperation with local neu-
rosurgeons, and standardization of material preservation.
Steve Clifford discussed the use of molecular stratifica-
tion of medulloblastoma moving forward. the International 
Society of paediatric Oncology (SIOp) pNet 3 clinical 
trial was retrospectively reviewed using the goldengate 
DNA methylation array (Illumina, San Diego, CA, USA) 
to analyze DNA extracted from formalin-fixed, paraffin-
embedded (FFpe) tumor samples. Dr. Clifford clearly 
showed that the four medulloblastoma subgroups can be 
identified using this technology [45].
Marc Remke discussed further dissection of the molecu-
lar subtypes of medulloblastoma by using methylation and 
expression profiling on samples from the Medulloblastoma 
Advanced genomic International Consortium (MAgIC). 
His data showed a still-evolving molecular classification of 
medulloblastoma. Although he identified the four disease 
subgroups, groups 3 and 4 demonstrated additional dis-
tinct subtypes. group 3 can be further stratified into sub-
types primarily based on the presence of MYC amplifica-
tion and chromosome 8 abnormalities. Further stratification 
of group 4 was less clear. Importantly, each group appears 
to have a different clinical outcome; thus, more work is 
needed to further delineate these groups and their impor-
tance to treatment.
paul Fisher presented opportunities for epidemiologic 
investigation of medulloblastoma, in particular investigat-
ing germline variants across regional or national popula-
tions. By elucidating these differences, we may discover 
further mechanisms of disease induction and progression.
paul Northcott outlined work investigating germline 
variations and their implications in the development of 
medulloblastoma. He raised the question of the gen-
eral contribution of known cancer genes that are mutated 
in the medulloblastoma germline and the importance of 
penetrance rate. to address this, Dr. Northcott will assess 
the incidence of germline single-nucleotide variations 
and insertions/deletions of genes by investigating the fre-
quency of causative germline copy number variants in 
medulloblastoma.
Brandon Wainwright presented his group’s work on 
dependence-receptor signaling in medulloblastoma. In 
particular, he discussed Neogenin1 (NEO1) [22], an axon-
guidance molecule involved in chemoattraction during 
axon growth. Low levels of NEO1 expression adversely 
affects prognosis in patients with SHH disease, but it is 
unclear how the molecule functions in this context. Dr. 
Wainwright stressed that NEO1 receptors and ligands could 
be therapeutic targets in the future.
Session 2: genomics and mouse models
Michael taylor presented a comparison of FFpe tumor 
samples of primary disease and relapsed tumor obtained 
from the same patients in a discovery cohort at the Hos-
pital for Sick Children in toronto. Dr. taylor showed evi-
dence that the molecular features of medulloblastoma do 
not switch between diagnosis and relapse. Furthermore, the 
patterns of relapse and recurrence are subgroup specific. For 
example, SHH medulloblastoma tends to recur locally, but 
groups 3 and 4 almost always recur with metastases. there 
are also emerging data on genetic aberrations (e.g., cytoge-
netic features and copy number variations) that discern clin-
ically significant prognostic subgroups. GLI2 amplification, 
MYCN amplification, 14q loss, and chromothripsis indicate 
poor prognosis in SHH medulloblastoma, and MYC ampli-
fication and isochromosome 17q are negative prognostic 
markers in group 3 tumors. In group 4, patients with chro-
mosome 11 loss or chromosome 17 gain tend to fare better 
and have a longer period to recurrence, but MYCN amplifi-
cation has no prognostic effect in this subgroup. Dr. taylor 
indicated that it is imperative that the genetic heterogene-
ity within the disease subgroups be defined. He proposed a 
“6-pack” of fluorescence in situ hybridization (FISH) tests 
(GLI2, MYC, 14q, 17p, 17q, and 11q) as a “pathology labo-
ratory-friendly” means to delineating the disease.
Dr. taylor also presented work from his laboratory 
investigating the role of membrane depolarization as a 
potential medulloblastoma tumor suppressor. glutamate is 
expressed during normal cerebellar development and drives 
tachyphylaxis to SHH protein in the progenitor cells in 
the external granular layer. glutamate signaling is down-
regulated in Ptch+/− mice and in human SHH medulloblas-
toma, compared to levels in normal cerebellum, suggesting 
opposing developmental roles of SHH and glutamate in 
normal cerebellar development and medulloblastoma.
Scott pomeroy discussed genetic and epigenetic changes 
that occur during medulloblastoma tumorigenesis. He is 
attempting to discern how medulloblastoma subtype-spe-
cific copy number alterations affect transcription by inter-
rogating protein–protein interaction databases. Many non-
recurrent perturbations in epigenetic machinery are found 
across all medulloblastoma subtypes that appear in network 
modules. Using these databases, Dr. pomeroy has found 
high-confidence interactions that, when plotted, display 
SHH-subtype networks of interactions.
David Jones presented data on the methylomic landscape 
of medulloblastoma and discussed different techniques to 
determine methylation trends in the genome. the first tech-
nique discussed was the Illumina Infinium HumanMeth-
ylation450 BeadChip array (450K array) which includes 
>4,50,000 probes covering essentially all genes, and is suf-
ficient to classify the subgroup of most tumor types with 
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a better match to gene expression profiling compared with 
the IHC markers assessed [10]. this non-subjective assay 
works well with FFpe material, as confirmed by compari-
son with results from assays of fresh-frozen samples.
the second technique Dr. Jones discussed was whole-
genome bisulfite sequencing (WgBS). this method is 
more expensive, requires more DNA, and is computation-
ally more challenging than the 450K arrays. Unlike the 
arrays, however, WgBS covers all Cpg’s; therefore, it 
provides a greater degree of accuracy in detecting differen-
tially methylated regions. A large number of medulloblas-
toma subgroup genes show methylation-expression corre-
lations. All WNt tumors and group 3 tumors demonstrate 
hypomethylation. Additionally, these medulloblastoma sub-
types almost exclusively demonstrate partially methylated 
domains, which consist of megabase-scale regions display-
ing hypomethylation overlapping with markers of hetero-
chromatin and reduced gene expression. the fact that genes 
within partially methylated domains tend to be expressed 
at very low levels and the rate of concurrent somatic muta-
tions is higher supports the hypothesis of compact chroma-
tin being less accessible to DNA repair.
David Jones also presented on behalf of Marcel Kool, 
who is investigating SHH subgroup-outcome prediction to 
SMO inhibition. Within the SHH-subtype of medulloblas-
toma, three subgroups can be distinguished based on muta-
tions: infants, children, and adults. Infant-SHH tumors tend 
to have a high rate of PTCH mutations and germline SUFU 
mutations, with few cases of MYCN and GLI2 amplification 
or TP53 mutations. tumors from patients aged 5–16 years 
show frequent TP53 mutations, which are often germline, 
and amplifications of GLI2 and MYCN. Adult-SHH medul-
loblastoma tumors show greater numbers of recurrent muta-
tions and more mutations per tumor than do pediatric tumors, 
and mutations in SMO are common in adult cases. LDe225, 
a SMO inhibitor currently being assessed in a phase III trial 
for SHH-positive medulloblastoma (http://clinicaltrials.
gov/ct2/show/NCt01708174) shows different sensitivities 
depending on mutation types. primary resistance to LDe225 
depends on the germline predisposition (e.g., SUFU muta-
tion) or presence of GLI2/MYCN amplifications. these data 
will be crucial for drug trials to identify the appropriate can-
didates to receive these novel agents.
Dan Williamson discussed identifying druggable targets 
in a mutagenesis-modifier screen of the Ptch+/− medul-
loblastoma model (Sleeping Beauty transposon system in 
mice). this model demonstrated that the Sleeping Beauty 
mutagenesis system in Ptch+/− mice perturbed a tran-
scription factor network, leading to the upregulation of 
Igf2, maintenance of medulloblastoma proliferation, and 
increased tumor frequency. It also highlighted the central 
role for Igf2 expression in medulloblastoma formation and 
identified Myt1L as a novel target for intervention.
Dr. Williamson’s presentation generated discussion on 
the role of mouse models in directing the medulloblastoma 
research agenda as a validation or discovery tool. eluci-
dating the tumorigenic event is essential to understanding 
the relevance of the model. A suggestion was put forward 
to establish a central repository of all mouse models (e.g., 
transgenic models, xenograft models, etc.) that would make 
the animals freely available to researchers worldwide and 
provide information about what drives each model.
Session 3: High-throughout drug screening—translating 
science into the clinic
Anang Shelat discussed the HtS program at St. Jude Chil-
dren’s Research Hospital. His group employs both target-
based and phenotypic HtS to prioritize compounds for 
drug development. Dr. Shelat provided an update on an 
HtS campaign targeting DDX3X, a DeAD-box RNA heli-
case that is mutated in approximately 50 % of human WNt 
medulloblastomas that have been sequenced [12, 39, 41]. 
Although DDX3X is not a validated drug target for medul-
loblastoma, the lack of quality small-molecule chemical 
tools to probe the function of this protein justified the need 
for screening. Dr. Shelat also applies a phenotypic-screening 
strategy using the Celltitre-glo® assay (promega, Madison, 
WI, USA), which is based on Atp consumption as a meas-
ure of cell proliferation and viability. the screening library 
was designed to cover bioactive chemical space using com-
pounds spanning a range of drug development times: short-
term (FDA-approved drugs or late-stage clinical candidates 
with known target or mechanism of action), intermediate-
term (pharmacophore-based compounds potentially target-
ing novel members from well-studied protein families such 
as kinases or nuclear hormone receptors), and long-term 
(rare scaffolds potentially targeting novel targets from less-
characterized protein families). the St. Jude drug-discovery 
pipeline consists of a number of steps, starting with building 
a model based on knowledge of human tumor and mouse 
genetics, then developing and validating an HtS-compatible 
assay, followed by primary screening at a single concentra-
tion of the drug, and secondary screening of dose responses. 
prior to in vivo efficacy studies, positive HtS hits are first 
prioritized using a washout assay to assess the longevity 
and mechanism of action, synergy testing with each other 
and standard-of-care agents, and pharmacokinetic (pK) 
analysis including an estimation of central nervous system 
(CNS) penetration. Dr. Shelat discussed the variability of 
HtS results, which stems in part from the functional con-
sequences of genetic variability in models, the influence of 
media and environmental factors on cell growth, and inter-
operator variability. He stressed the need to replicate HtS 
results in different labs to eliminate false positives early in 
the drug-discovery process.
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Jim Olson highlighted his group’s approach to HtS, 
stressing that integrity is key to this process. He defined 
integrity as “the concept of consistency of actions, val-
ues, methods, measures, principles, expectations, and out-
comes”. HtS efforts are futile unless future clinical tri-
als are considered and the best in vivo preclinical models 
are identified. Many potential drug candidates kill tumor 
cells in vitro, but that has little clinical relevance because 
metabolism, oxygen levels, and cell signaling in vitro are 
altered from those in the tumor’s natural environment. the 
point was raised that nearly all targeted drugs fail to cross 
the blood–brain barrier and will never benefit patients with 
newly diagnosed disease. However, during discussions it 
was suggested that drugs that are effective in vitro should 
not be discarded too quickly because they may yet be mod-
ified to facilitate crossing the blood–brain barrier. even if 
this is not achieved, these drugs may still provide important 
information on the mechanisms that drive tumor growth 
and survival.
Dr. Olson highlighted the two approaches one can take 
to HtS. First, HtS can be used as a tool to screen potential 
drugs based on their pK and pharmacologic data and iden-
tify potential therapies to translate directly into the clinic. 
Second, HtS can be used to increase our understanding 
of the biology of the tumors and then develop drugs that 
target the vulnerabilities identified. Dr. Olson also briefly 
commented on the use of knottins (small, diverse, and sta-
ble proteins) as drug scaffolds but acknowledged the many 
challenges associated with this approach. Knottins have 
a short half-life in serum, have issues with solubility, and 
exhibit poor folding in Escherichia coli and yeast. they are 
difficult to synthesize in the milligram quantities required, 
and it is expensive to produce diverse examples. In addi-
tion, knottins are not easy to use in medicinal chemistry. 
Finally, Dr. Olson emphasized the crucial importance of 
international collaboration in clinical trials to expedite drug 
development from patient to bench and back.
William Weiss discussed his group’s approach to MYC-
amplified medulloblastoma. SHH and group 3 tumors are 
often MYC-amplified, either nuclear or cytoplasmic. MYC 
is a highly stable protein that is generally thought to be 
undruggable, because it has no apparent surfaces for small-
molecule binding. Dr. Weiss’ group is attempting to bind 
MYC indirectly by using pI3K-pathway blockade or aurora 
kinase inhibitors, which can induce a novel and distinct 
conformation of aurora kinase A that is unable to stabilize 
MYCN.
Jae Cho continued the MYC theme, discussing his work 
on the genetic and chemical perturbations of MYC using 
a combination of high-throughput functional genomic 
screens, whole-genome shRNA sequencing, and chemi-
cal genome sequencing to identify and validate targets and 
generate lead compounds. His group has screened nearly 
2,000 compounds by using chemical biology screening and 
has identified the intolerance of reactive-oxygen species as 
a vulnerability of MYC-amplified medulloblastoma cells. 
Agents that produce reactive-oxygen species induced apop-
tosis and inhibited MYC-related gene expression signatures 
associated with poor outcome, while having minimal side 
effects on cells derived from the subventricular zone. these 
preliminary data need to be confirmed in in vivo systems. 
Other promising candidate drugs identified targeted Bet 
bromodomains in MYC-driven tumors and DDX3X in 
WNt-group and SHH-group tumors.
Clinton Stewart discussed preclinical pK studies in sup-
port of medulloblastoma drug development efforts and the 
relevance and importance of CNS penetrance to pK. the 
basic tenets he outlined included the importance of get-
ting the compound to the target, the relevant concentration 
and length of exposure at the target (washout experiments), 
and the unbound drug being the active moiety. Dr. Stew-
art went on to talk about model-based drug development 
to characterize the exposure–response relationship in pre-
clinical models [23] and the importance of performing pK 
studies in tumor-bearing animals, but he also emphasized 
that depending upon the purpose of the study non-tumor-
bearing mice could also be used. Knowing an agent’s pen-
etrance into normal brain tissue is equally important to 
knowing its penetrance into brain tumor tissue. the goals of 
pK studies are to assess the systemic and CNS drug distri-
bution in mouse models of pediatric brain tumors, to opti-
mize the dosing of drug (i.e., dosage, schedule, sequence) 
in efficacy studies, to relate these results to in vitro effi-
cacy studies (IC50 and IC90), and to obtain data to scale-up 
dosing for the candidate drugs moving into clinical trials. 
these goals should be organized and consistent, yet flex-
ible. Simply due to their vast number, the efficacies of all 
compounds cannot be studied; thus, a robust system to pri-
oritize and optimize compounds must be adopted. those 
compounds that are demonstrated active in screens using 
accurate tumor models should be prioritized. When mov-
ing a compound to the clinic, it is imperative to use pK and 
pharmacologic studies to guide dosing in efficacy studies 
to identify whether brain penetration is adequate to attain 
the desired target exposure based upon preclinical studies. 
For those compounds translated into the clinic, pK studies 
should then be performed to confirm that the exposure-time 
relationship observed in preclinical models is also observed 
in the clinic.
Session 4: Clinical trials—implementing advances into the 
next-generation protocols
Roger packer discussed the current clinical status of medul-
loblastoma. In recent years, overall survival has improved 
in patients older than 3 years, and quality of survival has 
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improved in infants with desmoplastic/nodular medul-
loblastoma. However, we still face the challenges of poor 
survival in patients with disseminated disease, and overall 
quality of survival is suboptimal for all children receiv-
ing radiotherapy plus chemotherapy. Dr. packer discussed 
the importance of gross total resection, the unclear role 
of surgery in treating disseminated tumors, and whether 
the efficacy of gross total resection on long-term survival 
is subgroup dependent. New radiotherapy techniques 
were addressed, and the question of whether any subset of 
medulloblastoma could be adequately treated with radio-
therapy alone or chemotherapy alone was raised. the role 
of biological chemotherapy, with respect to tumor sub-
groups, was also discussed.
Amar gajjar reported on the outcome of the most recent 
St. Jude medulloblastoma protocol (SJMB03) in which 
treatment was risk stratified. this trial enrolled more than 
400 patients, 330 of whom had medulloblastoma. Based 
on analysis of SJMB03 data, the following new risk crite-
ria for non-infant medulloblastoma have been adopted in 
the recently opened successor trial called, “A Clinical and 
Molecular Risk-Directed therapy for Newly Diagnosed 
Medulloblastoma” (SJMB12) (http://clinicaltrials.gov/
show/NCt01878617) (Fig. 1).
giles Robinson discussed exploring the new genomic 
and molecular findings to identify those patients most 
likely to suffer relapse and to use this information to 
develop new therapies to treat patients with relapsed 
medulloblastoma. He proposed a two-pronged approach 
to tackling this question. First, we must continue institu-
tional and small consortium phase I/II trials. these trials 
can be rapidly opened and appeal to pharmaceutical spon-
sors. However, problems may be encountered with small 
patient numbers, recruitment issues, and the long duration 
of such studies. Second, we must establish larger collabora-
tive trials, which are more efficient, have larger cohorts and 
quicker pipelines, and address specific biologic aims. phar-
maceutical companies may be more hesitant to participate 
in such trials, and potential conflicts about study ownership 
and authorship could arise.
François Doz discussed SIOp-europe’s new frontline 
average-risk medulloblastoma trial (SIOp-e pNet 5-MB), 
which will apply prospective biological stratification and 
will soon be open to enrollment. For patients older than 
3–5 years, the following selection criteria will be used: 
posterior fossa tumor, no metastasis on CNS magnetic 
resonance imaging, no residual disease after surgery (or 
<1.5 cm2 largest diameter), and negative cerebrospinal fluid 
cytology by lumbar puncture. patients with either LC/A 
medulloblastoma or N-MYC/C-MYC amplification are not 
eligible for this study. Stratification into low- or standard-
risk groups is based on the presence or absence of WNt 
features (defined by β-catenin nuclear immunopositivity 
by IHC and/or β-catenin mutation analysis) and low-risk 
clinical features. patients with low-risk medulloblastoma 
(WNt-medulloblastoma) will receive 23.4 gy CSI with 
a tumor bed boost to 55.4 gy, followed by reduced main-
tenance chemotherapy. those with standard-risk disease 
will be randomized to receive either radiotherapy alone 
or radiotherapy in combination with carboplatin similar to 
the treatment regimen of the Children’s Oncology group 
(COg) pilot study, with both treatment arms followed by 
maintenance chemotherapy.
Nicholas gottardo outlined the COg-proposed front-
line trial, a molecularly based stratification-feasibility study 
for children with newly diagnosed, average-risk medullo-
blastoma. three guiding principles were established before 
the study was designed: (1) work toward synchronizing all 
patients with medulloblastoma under one study for future 
biology-based stratification; (2) improve the survival rate 
with minimal additional adverse effects and reduced long-
term sequelae; (3) replace toxic agents with treatments that 
are less toxic yet still effective. this trial will provide the 
foundation for future phase III studies of medulloblas-
toma by introducing molecular analysis. the study will 
assess the feasibility of real-time molecular stratification 
and central pathology review. On the basis of currently 
applied clinical-risk criteria, histopathologic features, and 
molecular assessments, patients will be classified into two 
molecular subgroups: WNt-driven average-risk (defined by 
β-catenin nuclear immunopositivity by IHC and monosomy 
6 by FISH) and non-WNt-driven average-risk medullo-
blastoma. As in the SIOp-e pNet 5-MB study, patients 
with either LC/A medulloblastoma and/or N-MYC/C-MYC 
amplification will not be eligible for this study. the study 
will incorporate a reduced-therapy strategy for patients 
Fig. 1  New risk criteria for medulloblastoma in recently opened St. 
Jude frontline medulloblastoma protocol (SJMB12)
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with WNt-driven medulloblastoma. Upon completion 
of the feasibility components of the study, enrollment 
will continue for patients with average-risk, WNt-driven 
medulloblastoma.
Stefan Rutkowski discussed the treatment, concepts, 
subgroups, and challenges of medulloblastoma in young 
children and infants. CSI-free survival and neurocogni-
tion have become important outcome measures especially 
in young children with desmoplastic medulloblastoma 
or MBeN, who have a better prognosis than young chil-
dren with nondesmoplastic tumors [43]. performing rand-
omized, controlled trials can help to further improve treat-
ment results, but the conduct of such trials in relatively rare 
subgroups is challenging. Based on the results of a national 
phase II trial [42], the pNet working group of SIOp-e 
plans to initiate a randomized european trial for young 
children with desmoplastic medulloblastoma/MBeN with 
systemic chemotherapy with or without intraventricular 
methotrexate. Based on the results of a French pilot study, 
a randomized trial for treating young children with nondes-
moplastic medulloblastoma with induction chemotherapy, 
high-dose chemotherapy, and risk-adapted radiotherapy is 
also under development. Dr. Rutkowski encouraged inter-
national collaboration for studying this very small group of 
patients. He also discussed the need for better translation of 
the underlying biology into clinical trials and the need for 
inclusion criteria to be consistent across study groups.
Stefan pfister presented data showing that patients with 
tp53-SHH medulloblastoma have better overall survival 
after receiving standard therapy than after receiving high-
intensity treatment, regardless of the presence of meta-
static disease. therefore, this small but distinct subgroup of 
patients requires a different treatment approach, and given 
the very small number of patients affected by this disease, 
an international trial is warranted.
the last speaker of the meeting was Barry pizer, who 
discussed approaches to relapsed disease. He highlighted 
the plight of patients with relapsed disease after previous 
CSI, noting that the majority have disseminated disease. 
Despite receiving very intensive salvage regimens, includ-
ing megatherapy with autologous stem cell rescue, patients 
have very little chance of cure [9]. Dr. pizer presented 
data from four consecutive COg studies from 1989 that 
included a total of 620 patients. Of the 444 patients in the 
average-risk group, 87 (19 %) experienced disease relapse, 
as did 80 (45 %) of the 176 in the high-risk group. Dr. pizer 
noted that the high-risk group experienced relapse earlier. 
Five years after relapse, only 12 (7.2 %) patients were 
alive: 8 had suffered a local relapse, and 4 experienced a 
component of distant relapse. Similarly, of 340 children 
treated on the HIt-SIOp pNet 4 trial [15], 72 (20 %) suf-
fered relapse, and only 8 (11 %) were alive at 5-year fol-
low-up (5, alive with disease; 3, no evidence of disease).
Development of a medulloblastoma global action plan
In this section, discussions that took place at the end of 
each session and led to the formation of a medulloblastoma 
global action plan (Fig. 2) are summarized. A consensus 
was reached in several key areas, with the most important 
being that a novel classification scheme for medulloblas-
toma based on the four molecular subgroups, as well as 
histopathologic features, should be presented for consid-
eration in the upcoming fifth edition of the World Health 
Organization’s classification of tumours of the central nerv-
ous system. three other notable areas of agreement were 
as follows: (1) to establish a central repository of annotated 
mouse models that are readily accessible and freely availa-
ble to the international research community; (2) to institute 
common eligibility criteria between COg and the SIOp-
e and initiate joint or parallel clinical trials; (3) to share 
preliminary HtS data across discovery labs to hasten the 
development of novel therapeutics.
Summary of the pathology and molecular stratification 
session
Dr. pfister discussed data from his laboratory, which has 
identified a 20 % discordance rate between standard IHC 
methods and newer technologies (e.g., Nanostring and 
450K array profiling). given this and the fact that IHC 
markers cannot reliably distinguish between the four sub-
groups, the International Medulloblastoma Working group 
is considering whether using either of the new technologies 
should be standardized to aid in diagnosis and prognosti-
cation. to address this, the COg-proposed front-line trial 
will prospectively evaluate novel diagnostic techniques 
[10, 30, 45], in parallel with established (IHC and FISH) 
methodologies. In addition, the need to mandate subgroup 
classification at diagnosis and the value of this classifi-
cation for patients with relapsed disease to permit their 
enrollment on subgroup-specific targeted therapies was dis-
cussed. A motion was made that the published consensus 
molecular classification of medulloblastoma [49] should be 
adopted. Clear agreement was reached for a 4-group clas-
sification scheme to be proposed for inclusion in the next 
edition of the WHO guidelines. those groups will include 
WNt, SHH, group 3, and group 4 based on a combination 
of genomic, IHC, and traditional histologic evaluations. A 
fifth group, designated “not otherwise specified” or similar, 
could be included for rare tumors with a focal melanotic 
or rhabdomyoblastic phenotype, because these rare variants 
appear to fall outside the other four molecular subgroups 
(Robinson and ellison, unpublished), and for those tumors 
that are difficult to subclassify because of assay or tissue-
sampling limitations. the suggested medulloblastoma 
4-group classification algorithm is shown in table 2.
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the group agreed that the use of the proposed “6-pack” 
of FISH markers could also be considered for inclusion in 
the new WHO classification system, following validation in 
additional clinically defined cohorts. the importance of the 
clustering algorithms chosen to identify the biologic sig-
nals driving the groupings was highlighted, and attendees 
agreed that an independent validation cohort is needed to 
achieve consensus.
there was a great deal of discussion on whether blood 
and/or saliva samples should be included in baseline testing 
of the genomes of patients enrolled in future clinical trials 
to advance this evaluation. Analysis of patients on the basis 
of racial background was also discussed. the group agreed 
that, aside from the issues of self-reporting, there simply 
are not enough patients to achieve statistical power, and to 
date, no clear evidence has suggested that ethnicity affects 
outcome.
the SIOp-e pNet 5-MB trial will mandate both FFpe 
and fresh-frozen samples to support molecular diagnostics 
for risk stratification and future research studies. there 
was much debate about whether fresh-frozen tissue should 
be a requisite for trial enrollment. the pros and cons are 
detailed in table 3. Many believed that patients should not 
be excluded based on whether their care facilities have 
Fig. 2  Medulloblastoma Down Under proceedings action plan
Table 2  Suggested algorithm for molecular classification of medul-
loblastoma





WNt two of the following four must be met:
1. β-catenin mutation or β-catenin+ IHC and/or
2. Monosomy 6 and/or
3. Methylation-profiling pattern consistent with 
WNt or
4. gene expression pattern consistent with WNt
SHH two of the following four must be met:
1. gAB1 antibody and/or
2. SHH signaling-specific mutation and/or
3. Methylation-profiling pattern consistent with 
SHH or
4. gene expression pattern consistent with SHH
group 3 One of the following must be met:
1. Methylation-profiling pattern or
2. gene expression pattern consistent with 
group 3
group 4 One of the following must be met:
1. Methylation-profiling pattern or
2. gene expression pattern consistent with 
group 4
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the capacity to obtain, store, and ship fresh-frozen tissue. 
Because FFpe tumor samples provide reliable results on 
450K array testing, mandating submission of fresh-frozen 
tissue raised an ethical conflict, given the implications that 
knowledge of subgroup has the potential to more accurately 
guide treatment (e.g., reduced intensity of CSI in patients 
with WNt medulloblastoma). Application of this exclu-
sion criterion may also result in loss of statistical power, 
particularly in the case of the rarer medulloblastoma sub-
types. Most attendees felt that with proper education both 
sample types could be attained and would provide optimal 
material for biological studies. Simon Bailey highlighted a 
pilot project in the UK that is looking at this question. He 
reported that the response from oncologists, neurosurgeons, 
and neuropathologists has been very good.
In the end, the group agreed that submitting fresh-frozen 
samples and FFpe tissue samples is preferable and should 
be highly encouraged. given the non-negligible risk of 
failure of molecular risk evaluation using FFpe specimens 
and the importance for ongoing biologic discovery during 
prospective studies to provide validated data for new prog-
nostic factors and therapeutic targets, fresh-frozen tissue 
will continue to be mandated for enrollment on the SIOp-e 
pNet 5-MB study. In addition, the proposed COg front-
line average-risk medulloblastoma clinical trial will man-
date fresh-frozen tumor tissue.
Summary of the genomics and mouse models session
the group agreed that centers for central review of classic 
and novel disease markers/signatures should be established. 
to this end, the SIOp-e pNet 5-MB study and the pro-
posed COg front-line average-risk medulloblastoma clini-
cal trial will both use central reference laboratories based 
in europe and the USA, respectively. to support ongoing 
biological studies as part of prospective clinical trials, edu-
cational outreach for neurosurgeons and staff at smaller 
centers should be initiated.
the group also agreed that disease-associated germline 
mutations should be explored and germline analysis should 
be performed for those children who experience second-
ary malignancies. preclinical models should continue to be 
developed for assessment of targeted therapy, and a central 
repository or data system is needed for modeling medullo-
blastoma. Jim Olson has already begun preparing a web-
based system of his laboratory’s available mouse models 
for sharing and has volunteered to expand this effort to 
the global medulloblastoma community. It was proposed 
that the existing complete datasets should be combined, 
and information should be freely available as a means of 
increasing the breadth of knowledge about childhood 
medulloblastoma, thereby facilitating our common goal of 
understanding this disease.
Summary of the high-throughout drug screening: 
translating science into the clinic session
Discussion centered on prioritizing compounds, and 
although microdialysis disrupts the blood–brain barrier, it 
was advocated as a robust means of assessing blood–brain 
barrier penetrance. Setting up a microdialysis system is 
not a trivial endeavor; therefore, collaborations with cent-
ers that have core facilities to support such studies were 
encouraged. the group agreed that selecting important 
targets will be essential to success in this heterogeneous 
patient population. Not every medulloblastoma is simi-
lar and informed; thus, model-based drug development in 
well-understood models must be used to test the appropri-
ate compounds. prior to clinical implementation, the expo-
sure–response relationship should be characterized in pre-
clinical models.
the concept of open-source chemistry was suggested to 
share promising compounds at an earlier stage in develop-
ment. this approach would facilitate more thorough assess-
ments by multiple investigators using several different mod-
els and increase our knowledge of the mechanism of action 
and efficacy of new compounds. We must be expeditious 
in drug development, which will ultimately lead to more 
robust preclinical testing of compounds and better con-
cordance between laboratory groups. Concern was voiced 
that as medulloblastoma is further subdivided, the rarity of 
some subgroups may limit our ability to adequately power 
clinical trials to assay responses in small subgroups. thus, 
in addition to developing subgroup-specific therapies, we 
should also develop broad-ranging agents.
Summary of the clinical trials: implementing advances 
into the next-generation protocols session
As a result of new information that came to light during the 
previous session and given the increasing awareness of the 
Table 3  pros and cons of mandating fresh-frozen tissue for enroll-
ment on a therapeutic medulloblastoma clinical trial
FFPE formalin-fixed, paraffin-embedded
pros Cons
Support molecular diagnostics given 
risk of failure of molecular risk  
evaluation using FFpe specimens  
or development of a novel molecular 
test at a later point
Lower recruitment with 
consequent loss of statisti-
cal power
Optimal material for ongoing and  
future biologic discovery studies
potential ethical conflict
provide validated data for new  
prognostic factors and therapeutic 
targets
Variable capacity across 
institutions to obtain, store, 
and ship fresh-frozen tissue
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contribution of predisposing germline mutations to medul-
loblastoma, the group agreed that going forward, all medul-
loblastoma clinical trial protocols should include obtaining 
detailed family cancer histories from each participant. A 
number of general issues that need to be considered when 
contemplating altering clinical treatments were also dis-
cussed. these include proof of benefit, safety of the novel 
treatment compared to that of conventional treatments, 
potential neurocognitive effects, damage to the neuronal 
niche, and whether the treatment would be appropriate for 
primary versus secondary tumors.
there was little question that treatment must be assessed 
in molecularly defined subsets of patients, and given that 
study cohorts are most likely to include multiple subgroups, 
this will require large patient numbers. therefore, interna-
tional collaborations, if they can be undertaken efficiently, 
will greatly facilitate this approach. the group agreed that a 
common set of inclusion and response criteria for COg and 
SIOp-e trials should be established, and joint or parallel 
clinical trials should be initiated. WNt-medulloblastoma 
represents an ideal subtype of disease to investigate jointly. 
Researchers studying non-Hodgkin lymphoma, osteosar-
coma, and hepatoblastoma have set a precedent for global/
transatlantic studies; however, those studies were challeng-
ing due to clinical trials regulations.
Discussions then focused on future studies addressing 
the natural history of relapse and the dangers of selection 
bias when analyzing data from individual reports. Whether 
a curative approach using conventional therapy is reason-
able in some patients was debated. If so, the determinants 
that justify this approach (e.g., biology or pattern of relapse) 
must be defined. For those patients with relapsed disease 
who have not undergone CSI, the treatment strategy is fairly 
clear. In the case of disseminated disease at relapse after 
CSI, most felt that a second course of radiotherapy or sur-
gery is not recommended, but no consensus was reached. For 
those patients who suffer a localized relapse (posterior fossa 
or metastatic), most attendees agreed that a second surgical 
resection is appropriate if followed by adjuvant therapy. the 
key question is—what adjuvant therapy should be used?
enrolling all patients who experience relapse into early-
phase clinical trials was discussed; however, at present this 
is not in practice. given the various molecular subtypes 
of medulloblastoma, it will be important to ensure that 
patients with relapsed disease receive subgroup-appropriate 
therapies (e.g., SMO inhibitors or future DDX3X inhibi-
tors). the MeMMAt (Medulloblastoma european Multia-
gent Metronomic Antiangiogenic trial) (http://clinicaltrials.
gov/show/NCt01356290) was briefly discussed, and all 
agreed that we must develop a consensus on the treatment 
of relapsed disease and standardize quality-control proce-
dures, eligibility, and treatment-response criteria between 
the COg and SIOp-e trials.
the group also discussed collecting tumor samples at 
autopsy. Most centers do not collect such samples. tumor 
samples obtained at autopsy are not as fresh as those 
obtained during surgical resection, and yeast contamination 
may be a problem; however, the tissue samples are still valu-
able, especially if collected within 12 h of death. Samples 
collected during this period provide adequate amounts of 
good-quality DNA and RNA. Sample collection as much as 
24 h after death is acceptable for xenograft models of aggres-
sive tumors, despite low cell viability. Directly establishing 
cell lines from tumor samples obtained 24 h after death can, 
however, be very challenging. therefore, generating cell 
lines from xenograft model tumors may be a better approach.
Finally, the value of phase 0 trials for localized or dis-
seminated medulloblastoma was discussed. Mandating 
treatment before brain biopsy and continuing treatment 
thereafter was also suggested.
Conclusion and future directions
Medulloblastoma Down Under 2013 brought together lead-
ing researchers and clinicians to develop a global action 
plan to defeat this disease. the combination of thought-
provoking presentations and intensely focused working 
groups resulted in the development of our Medulloblastoma 
global Action plan, which outlines the key areas in which a 
consensus was reached for what needs to be done to move 
the field forward. We need to classify medulloblastoma into 
the four molecular subgroups; WNt, SHH, group 3, and 
group 4. the techniques adopted to do this must be reliable 
and globally applicable. Currently, molecular subgroups 
are clinically informative for the WNt and SHH subgroups 
only, because rational individual therapies for group 3 and 
group 4 do not exist. therefore, data on these latter two 
subgroups still need to be collected as a basis for future 
developments. It is also paramount that molecular discov-
ery of additional medulloblastoma subgroups be linked to 
clinical parameters so that such subgroups are clinically 
relevant.
Despite intense debate, a number of important issues 
remained unresolved at the conclusion of the meeting. 
these include mandating fresh-frozen tissue for enroll-
ment in clinical trials, the optimal technology to analyze 
specimens (Illumina 450K array vs. Nanostring diagnostics 
vs. WgBS vs. goldengate DNA methylation assay) and 
when to introduce novel targeted therapies (at diagnosis 
or upon relapse of disease). these are all important points 
that must be considered and will be addressed again at the 
2014 Meeting of the Medulloblastoma Working group and 
beyond, until a consensus is reached.
In conclusion, the progress made at this meeting high-
lights the value of international working groups as a novel 
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vehicle for collaborative research. this template could be 
applied to other fields to devise global action plans address-
ing all aspects of the disease of interest, from improved 
disease classification, stratification, and drug targeting to 
superior treatment regimens to be assessed in collabora-
tive international clinical trials. As new medulloblastoma 
subtypes are identified, the patient population of each sub-
group will decrease, making it more difficult to recruit suf-
ficient numbers of patients to determine optimal therapy. 
the group agreed that the medulloblastoma research com-
munity must work together to overcome regulatory, geo-
graphical, and competitive barriers and initiate joint clini-
cal trials. Unless we find a way to overcome these hurdles, 
we will struggle to expeditiously identify and introduce 
optimal therapies into clinical practice.
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